BioCentury
ARTICLE | Financial News

Aslan raises $22 million in series B

October 10, 2013 11:46 PM UTC

Aslan Pharmaceuticals Pte. Ltd. (Singapore) raised $22 million in a series B round led by new investor Cenova Ventures. New investors Morningside Group; and XinChen Ventures also participated along with existing investors BioVeda Capital; and Sagamore Bioventures. Aslan's ASLAN001 is in Phase II testing to treat gastric cancer. The company has exclusive worldwide rights to the oral small molecule inhibitor of EGFR and HER2 from Array BioPharma Inc. (NASDAQ:ARRY). ...